药物血栓预防基础上加用间歇充气加压对重症患者静脉血栓预防的作用
该随机对照试验纳入ICU入院48小时内的成人患者2003例,比较在药物血栓预防(普通肝素或低分子量肝素)基础上加用每日至少18小时间歇充气加压(充气加压组991例)与单用药物血栓预防(对照组1012例)。主要终点为随机化后第3个日历日起每周两次下肢超声检测的新发近端下肢深静脉血栓,充气加压组37/957例(3.9%)vs 对照组41/985例(4.2%),相对危险度0.93(95%CI 0.60–1.44,P=0.74),无显著差异。静脉血栓栓塞症(肺栓塞或任何下肢深静脉血栓)充气加压组103/991例(10.4%)vs 对照组95/1012例(9.4%),相对危险度1.11(95%CI 0.85–1.44);90天全因死亡充气加压组258/990例(26.1%)vs 对照组270/1011例(26.7%),相对危险度0.98(95%CI 0.84–1.13)。结论为在药物血栓预防的重症患者中,加用间歇充气加压未显著降低近端下肢深静脉血栓发生率。
要点
- 主要终点新发近端下肢深静脉血栓:充气加压组37/957例(3.9%)vs 对照组41/985例(4.2%),相对危险度0.93(95%CI 0.60–1.44,P=0.74),无显著差异。
- 静脉血栓栓塞症(肺栓塞或任何下肢深静脉血栓):充气加压组103/991例(10.4%)vs 对照组95/1012例(9.4%),相对危险度1.11(95%CI 0.85–1.44)。
- 90天全因死亡:充气加压组258/990例(26.1%)vs 对照组270/1011例(26.7%),相对危险度0.98(95%CI 0.84–1.13)。
- 间歇充气加压实际使用中位每日22小时(四分位距21–23),中位使用7天(四分位距4–13)。
- 入组为ICU入院48小时内的成人(按各中心标准≥14、≥16或≥18岁),且均在接受普通肝素或低分子量肝素药物血栓预防。
适用人群与场景
- 参与中心按当地标准判定为成人(≥14、≥16或≥18岁)的患者,于入住ICU后48小时内随机分组。
- 所有患者均接受药物血栓预防,方案为普通肝素或低分子量肝素。
处置流程与药物剂量
- 充气加压组在药物血栓预防(普通肝素或低分子量肝素)基础上加用间歇充气加压,每日至少18小时;实际使用中位每日22小时(四分位距21–23),中位使用7天(四分位距4–13)。
- 对照组单用药物血栓预防(普通肝素或低分子量肝素)。
研究设计与关键结果
- 多中心随机对照试验,2003例ICU患者随机分为充气加压组991例与对照组1012例。
- 主要终点新发近端下肢深静脉血栓(随机化后第3个日历日起每周两次下肢超声检测至ICU出院、死亡、恢复完全活动或试验第28天,以先发生者为准):充气加压组37/957例(3.9%)vs 对照组41/985例(4.2%),相对危险度0.93(95%CI 0.60–1.44,P=0.74)。
- 静脉血栓栓塞症(肺栓塞或任何下肢深静脉血栓):充气加压组103/991例(10.4%)vs 对照组95/1012例(9.4%),相对危险度1.11(95%CI 0.85–1.44)。
- 90天全因死亡:充气加压组258/990例(26.1%)vs 对照组270/1011例(26.7%),相对危险度0.98(95%CI 0.84–1.13)。
证据类型、等级与局限
- 证据类型:随机对照试验(PREVENT,ClinicalTrials.gov NCT02040103;Current Controlled Trials ISRCTN44653506)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU内已接受普通肝素或低分子量肝素药物血栓预防的成人患者,加用间歇充气加压未显著降低近端下肢深静脉血栓发生率,主要终点相对危险度0.93(95%CI 0.60–1.44,P=0.74)。
- 静脉血栓栓塞症与90天全因死亡在两组间无显著差异(相对危险度分别为1.11,95%CI 0.85–1.44;0.98,95%CI 0.84–1.13)。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether adjunctive intermittent pneumatic compression in critically ill patients receiving pharmacologic thromboprophylaxis would result in a lower incidence of deep-vein thrombosis than pharmacologic thromboprophylaxis alone is uncertain.
METHODS: We randomly assigned patients who were considered adults according to the local standards at the participating sites (≥14, ≥16, or ≥18 years of age) within 48 hours after admission to an intensive care unit (ICU) to receive either intermittent pneumatic compression for at least 18 hours each day in addition to pharmacologic thromboprophylaxis with unfractionated or low-molecular-weight heparin (pneumatic compression group) or pharmacologic thromboprophylaxis alone (control group). The primary outcome was incident (i.e., new) proximal lower-limb deep-vein thrombosis, as detected on twice-weekly lower-limb ultrasonography after the third calendar day since randomization until ICU discharge, death, attainment of full mobility, or trial day 28, whichever occurred first.
RESULTS: A total of 2003 patients underwent randomization - 991 were assigned to the pneumatic compression group and 1012 to the control group. Intermittent pneumatic compression was applied for a median of 22 hours (interquartile range, 21 to 23) daily for a median of 7 days (interquartile range, 4 to 13). The primary outcome occurred in 37 of 957 patients (3.9%) in the pneumatic compression group and in 41 of 985 patients (4.2%) in the control group (relative risk, 0.93; 95% confidence interval [CI], 0.60 to 1.44; P = 0.74). Venous thromboembolism (pulmonary embolism or any lower-limb deep-vein thrombosis) occurred in 103 of 991 patients (10.4%) in the pneumatic compression group and in 95 of 1012 patients (9.4%) in the control group (relative risk, 1.11; 95% CI, 0.85 to 1.44), and death from any cause at 90 days occurred in 258 of 990 patients (26.1%) and 270 of 1011 patients (26.7%), respectively (relative risk, 0.98; 95% CI, 0.84 to 1.13).
CONCLUSIONS: Among critically ill patients who were receiving pharmacologic thromboprophylaxis, adjunctive intermittent pneumatic compression did not result in a significantly lower incidence of proximal lower-limb deep-vein thrombosis than pharmacologic thromboprophylaxis alone. (Funded by King Abdulaziz City for Science and Technology and King Abdullah International Medical Research Center; PREVENT ClinicalTrials.gov number, NCT02040103; Current Controlled Trials number, ISRCTN44653506.).
参考来源
- Arabi YM, Al-Hameed F, Burns KEA, et al. Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis. N Engl J Med. 2019. PMID: 30779530. doi:10.1056/NEJMoa1816150
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。